Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer

作者: Nicole M Reusser , Heather J Dalton , Sunila Pradeep , Vianey Gonzalez-Villasana , Nicholas B Jennings

DOI: 10.4161/CBT.29184

关键词:

摘要: Purpose Bisphosphonates have been shown to inhibit and deplete macrophages. The effects of bisphosphonates on other cell types in the tumor microenvironment insufficiently studied. Here, we sought determine ovarian cancer angiogenesis growth via their effect microenvironment, including macrophage, endothelial populations. Experimental Design Using vitro vivo models, examined clodronate macrophage density, overall size metastasis. Results Clodronate inhibited secretion pro-angiogenic cytokines by cells macrophages, decreased migration capillary tube formation. In treated mice, significantly size, number nodules, tumor-associated macrophages density. Conclusions Clodronate is a potent inhibitor angiogenesis. These results highlight as potential therapeutic for cancer.

参考文章(18)
M Hall, C Gourley, I McNeish, J Ledermann, M Gore, G Jayson, T Perren, G Rustin, S Kaye, Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer. ,vol. 108, pp. 250- 258 ,(2013) , 10.1038/BJC.2012.541
Caroline Baer, Mario Leonardo Squadrito, M. Luisa Iruela-Arispe, Michele De Palma, Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches Experimental Cell Research. ,vol. 319, pp. 1626- 1634 ,(2013) , 10.1016/J.YEXCR.2013.03.026
M.C. Winter, R.E. Coleman, Bisphosphonates in the adjuvant treatment of breast cancer. Clinical Oncology. ,vol. 25, pp. 135- 145 ,(2013) , 10.1016/J.CLON.2012.10.010
Peter Carmeliet, Rakesh K. Jain, Molecular mechanisms and clinical applications of angiogenesis Nature. ,vol. 473, pp. 298- 307 ,(2011) , 10.1038/NATURE10144
Paulo Rodrigues, Flavio O. Hering, Alex Meller, Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study. Cancer Research and Treatment. ,vol. 43, pp. 231- 235 ,(2011) , 10.4143/CRT.2011.43.4.231
S. D. Hafeman, D. Varland, S. W. Dow, Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells Veterinary and Comparative Oncology. ,vol. 10, pp. 44- 56 ,(2012) , 10.1111/J.1476-5829.2011.00274.X
D. Ribatti, N. Maruotti, B. Nico, V. Longo, D. Mangieri, A. Vacca, F. Cantatore, Clodronate inhibits angiogenesis in vitro and in vivo Oncology Reports. ,vol. 19, pp. 1109- 1112 ,(2008) , 10.3892/OR.19.5.1109
S M Zeisberger, B Odermatt, C Marty, A H M Zehnder-Fjällman, K Ballmer-Hofer, R A Schwendener, Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer. ,vol. 95, pp. 272- 281 ,(2006) , 10.1038/SJ.BJC.6603240
Abigail F. Welford, Daniela Biziato, Seth B. Coffelt, Silvia Nucera, Matthew Fisher, Ferdinando Pucci, Clelia Di Serio, Luigi Naldini, Michele De Palma, Gillian M. Tozer, Claire E. Lewis, TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice Journal of Clinical Investigation. ,vol. 121, pp. 1969- 1973 ,(2011) , 10.1172/JCI44562